Yuan Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yuan Huang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Dan Zhou
Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, China
7 shared publicationsYun Jin
Sichuan University
5 shared publicationsXi Zhu
Sichuan University
4 shared publicationsXuan Qin
Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University ChengduPR China
4 shared publicationsZhi-Rong Zhang
Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 610041, Sichuan, PR China
4 shared publicationsZhirong Zhang
Sichuan University
3 shared publications
Latest Publications
- 15 January 2013
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 40 (2) , 163-171
Investigation of the mechanisms of improved oral bioavailability of bergenin using bergenin–phospholipid complex
Aim: The purpose of this study was to investigate the detailed mechanisms of oral absorption enhancement of bergenin (BN) using BN–phospholipid complex (BPC). Methods: Multiple models such as ex vivo everted rat gut sac model and in vitro Caco-2 cell model were used. Meanwhile, the effect of chitosan on the enhancement of the permeability of BPC was evaluated. Results: The limited absorption of BN was significantly improved in both ex vivo everted rat gut sac model and in vitro Caco-2 cell model when combined with phospholipid. The transport of BPC was uppermost 5.19-fold higher than that of BN. The results of ex vivo everted rat gut sac model showed that small intestine was a more suitable site for the absorption of BN and BPC than colon. Passive diffusion was the only way employed in the transport of BN, while BPC could transport across enterocytes by both passive diffusion and active transport which was found to be the clathrine-dependent receptor-mediated endocytosis. The absorption of BN was barely improved by the physical mixture of BN and phospholipid due to lack of stable intermolecular interactions. Moreover, the addition of chitosan could open the tight junctions of intestinal epithelial cells, thus significantly increasing the transport of BPC via paracellular route. Conclusions: Totally different mechanisms, which led to the enhanced oral bioavailability, were utilized in the uptake and transport process of BPC compared with BN. These results would be of significance for the future development of oral delivery systems of BN.
- 15 January 2013
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 40 (2) , 163-171
Investigation of the mechanisms of improved oral bioavailability of bergenin using bergenin–phospholipid complex
Aim: The purpose of this study was to investigate the detailed mechanisms of oral absorption enhancement of bergenin (BN) using BN–phospholipid complex (BPC). Methods: Multiple models such as ex vivo everted rat gut sac model and in vitro Caco-2 cell model were used. Meanwhile, the effect of chitosan on the enhancement of the permeability of BPC was evaluated. Results: The limited absorption of BN was significantly improved in both ex vivo everted rat gut sac model and in vitro Caco-2 cell model when combined with phospholipid. The transport of BPC was uppermost 5.19-fold higher than that of BN. The results of ex vivo everted rat gut sac model showed that small intestine was a more suitable site for the absorption of BN and BPC than colon. Passive diffusion was the only way employed in the transport of BN, while BPC could transport across enterocytes by both passive diffusion and active transport which was found to be the clathrine-dependent receptor-mediated endocytosis. The absorption of BN was barely improved by the physical mixture of BN and phospholipid due to lack of stable intermolecular interactions. Moreover, the addition of chitosan could open the tight junctions of intestinal epithelial cells, thus significantly increasing the transport of BPC via paracellular route. Conclusions: Totally different mechanisms, which led to the enhanced oral bioavailability, were utilized in the uptake and transport process of BPC compared with BN. These results would be of significance for the future development of oral delivery systems of BN.
- 29 May 2012
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 35 (5) , 839-850
Preparation and characterization of a novel pH-sensitive coated microsphere for duodenum-specific drug delivery
- 29 May 2012
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 35 (5) , 839-850
Preparation and characterization of a novel pH-sensitive coated microsphere for duodenum-specific drug delivery
- 10 February 2012
- Published by Springer Nature in Journal of Materials Science: Materials in Medicine
- Vol. 23 (4) , 983-990
Preparation and characterization of novel multi-core chitosan microspheres for stomach-specific delivery of hydrophilic antibiotics
Insufficient gastric mucosa drug concentration and short contact time were the main reason for the lack of eradication efficacy of Helicobacter pylori for peptic ulcer patients. Novel multi-core chitosan microspheres were prepared for stomach-specific delivery of hydrophilic antibiotics for the treatment of peptic ulcer. Chitosan microspheres with multiple Eudragit L100 cores were easily prepared by a new emulsification/coagulation encapsulating method. Swelling behaviors, surface amino groups and mucin absorption ability were investigated and the formulation that showed best mucoadhesive potential was adopted. The multi-core chitosan microspheres exhibited good mucoadhesiveness as well as controlled release manner for incorporated antibiotics in acidic environment. The release rate could be easily modulated with accumulative release ranging from 47.3 to 79.3% in 6 h. Accordingly, the multi-core chitosan microspheres could serve as a satisfactory vehicle for stomach-specific delivery of hydrophilic antibiotics.
- 10 February 2012
- Published by Springer Nature in Journal of Materials Science: Materials in Medicine
- Vol. 23 (4) , 983-990
Preparation and characterization of novel multi-core chitosan microspheres for stomach-specific delivery of hydrophilic antibiotics
Insufficient gastric mucosa drug concentration and short contact time were the main reason for the lack of eradication efficacy of Helicobacter pylori for peptic ulcer patients. Novel multi-core chitosan microspheres were prepared for stomach-specific delivery of hydrophilic antibiotics for the treatment of peptic ulcer. Chitosan microspheres with multiple Eudragit L100 cores were easily prepared by a new emulsification/coagulation encapsulating method. Swelling behaviors, surface amino groups and mucin absorption ability were investigated and the formulation that showed best mucoadhesive potential was adopted. The multi-core chitosan microspheres exhibited good mucoadhesiveness as well as controlled release manner for incorporated antibiotics in acidic environment. The release rate could be easily modulated with accumulative release ranging from 47.3 to 79.3% in 6 h. Accordingly, the multi-core chitosan microspheres could serve as a satisfactory vehicle for stomach-specific delivery of hydrophilic antibiotics.
- 30 December 2011
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 38 (10) , 1280-1288
Formulation and evaluation of novel coated floating tablets of bergenin and cetirizine dihydrochloride for gastric delivery
A novel coated gastric floating drug-delivery system (GFDDS) of bergenin (BN) and cetirizine dihydrochloride (CET) was developed. First, the pharmacodynamic studies were performed and the results revealed that the new compounds of bergenin/cetirizine dihydrochloride had comparative efficacy as commercial products (bergenin/chlorphenamine maleate) but with fewer side effects on central nervous system (CNS). Subsequently, bergenin was formulated as an extended-release core tablet while cetirizine dihydrochloride was incorporated into the gastric coating film for immediate release. The formulation of GFDDS was optimized by CET content uniformity test, in vitro buoyancy and drug release. Herein, the effects of sodium bicarbonate (effervescent), hydroxypropyl methylcellulose (HPMC, matrix polymer) and coating weight gain were investigated respectively. The optimized GFDDS exhibited good floating properties (buoyancy lag time < 2 min; floating duration > 10 h) and satisfactory drug-release profiles (immediate release of CET in 10 min and sustained release of BN for 12 h). In vivo gamma scintigraphy proved that the optimized GFDDS could retain in the stomach with a prolonged gastric retention time (GRT) of 5 h, and the coating layer showed no side effect for gastric retention. The novel coated gastric floating drug-delivery system offers a new approach to enhance BN’s absorption at its absorption site and the efficacy of both CET and BN.
- 30 December 2011
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 38 (10) , 1280-1288
Formulation and evaluation of novel coated floating tablets of bergenin and cetirizine dihydrochloride for gastric delivery
A novel coated gastric floating drug-delivery system (GFDDS) of bergenin (BN) and cetirizine dihydrochloride (CET) was developed. First, the pharmacodynamic studies were performed and the results revealed that the new compounds of bergenin/cetirizine dihydrochloride had comparative efficacy as commercial products (bergenin/chlorphenamine maleate) but with fewer side effects on central nervous system (CNS). Subsequently, bergenin was formulated as an extended-release core tablet while cetirizine dihydrochloride was incorporated into the gastric coating film for immediate release. The formulation of GFDDS was optimized by CET content uniformity test, in vitro buoyancy and drug release. Herein, the effects of sodium bicarbonate (effervescent), hydroxypropyl methylcellulose (HPMC, matrix polymer) and coating weight gain were investigated respectively. The optimized GFDDS exhibited good floating properties (buoyancy lag time < 2 min; floating duration > 10 h) and satisfactory drug-release profiles (immediate release of CET in 10 min and sustained release of BN for 12 h). In vivo gamma scintigraphy proved that the optimized GFDDS could retain in the stomach with a prolonged gastric retention time (GRT) of 5 h, and the coating layer showed no side effect for gastric retention. The novel coated gastric floating drug-delivery system offers a new approach to enhance BN’s absorption at its absorption site and the efficacy of both CET and BN.
- 15 July 2011
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 413 (1-2) , 110-118
A novel microsphere with a three-layer structure for duodenum-specific drug delivery
- 15 July 2011
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 413 (1-2) , 110-118
A novel microsphere with a three-layer structure for duodenum-specific drug delivery
- 13 May 2011
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 17 (6) , 719-729
Effects of degree of quaternization on the preparation and characterization of insulin-loaded trimethyl chitosan polyelectrolyte complexes optimized by central composite design
The aim of the present study was to investigate the effects of varying degrees of quaternization (DQ: 22, 35 and 41%) on the preparation and characterization of insulin (INS)-loaded polyelectrolyte complexes (PECs) prepared by N-trimethyl chitosan chloride (TMC). A two factor-five level central composite design was used for the optimization. The concentrations of INS and TMC were defined as independent variables, while the entrapment efficiency (EE%) and loading efficiency (LE%) as dependent variables. The three optimized INS-TMC PECs were characterized for their size, zeta potential, EE% and LE%. The morphology and electrostatic interaction of PECs were evaluated. Then, the stability in the enzyme solution and in vitro release as well as mucoadhesive properties of the three PECs were all investigated. The results showed that the size and EE% of the optimum formulations were significantly decreased using TMC of higher DQ, while the zeta potential and LE% were slightly influenced by DQ. The stability assay exhibited partial protection of TMC PECs, and the better protective effect was observed for PECs of higher DQ. The in vitro release study presented different initial and sustained release behaviors of INS-TMC PECs and the mucin adsorption study confirmed a positive correlation between the DQ and the mucoadhesive property of PECs.
- 13 May 2011
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 17 (6) , 719-729
Effects of degree of quaternization on the preparation and characterization of insulin-loaded trimethyl chitosan polyelectrolyte complexes optimized by central composite design
The aim of the present study was to investigate the effects of varying degrees of quaternization (DQ: 22, 35 and 41%) on the preparation and characterization of insulin (INS)-loaded polyelectrolyte complexes (PECs) prepared by N-trimethyl chitosan chloride (TMC). A two factor-five level central composite design was used for the optimization. The concentrations of INS and TMC were defined as independent variables, while the entrapment efficiency (EE%) and loading efficiency (LE%) as dependent variables. The three optimized INS-TMC PECs were characterized for their size, zeta potential, EE% and LE%. The morphology and electrostatic interaction of PECs were evaluated. Then, the stability in the enzyme solution and in vitro release as well as mucoadhesive properties of the three PECs were all investigated. The results showed that the size and EE% of the optimum formulations were significantly decreased using TMC of higher DQ, while the zeta potential and LE% were slightly influenced by DQ. The stability assay exhibited partial protection of TMC PECs, and the better protective effect was observed for PECs of higher DQ. The in vitro release study presented different initial and sustained release behaviors of INS-TMC PECs and the mucin adsorption study confirmed a positive correlation between the DQ and the mucoadhesive property of PECs.
- 11 January 2011
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 17 (4) , 443-456
A novel strategy for encapsulating poorly soluble drug into nanostructured lipid carriers for intravenous administration
The present study aimed to formulate dexamethasone (DXM), a poorly soluble drug, into nanostructured lipid carriers (NLCs) for intravenous administration by employing a phospholipids complex. Initially, dexamethasone-phospholipids complex (DPC) was synthesized and characterized. Subsequently, DPC was entrapped into NLCs and the process was optimized using spherical symmetric design-surface response methodology. Then, the characteristics, in vitro release behavior and physical stability of the optimized DPC loaded NLCs (DPC-NLCs) were investigated. Comparison between DPC-NLCs and free DXM loaded NLCs was also conducted in the aspects of particle size, entrapment efficiency (EE), drug loading efficiency (DL), initial release and zeta potential. The results showed the optimized DPC-NLCs were prepared with an average size of 189.33 ± 0.58 nm, EE of 89.82 ± 1.64%, DL of 2.13 ± 0.13% and good physical stability for 30 days. In vitro release profile exhibited an initial burst release followed by a prolonged release. Compared with free DXM loaded NLCs, the EE and DL of DPC-NLCs were higher while the initial release was lower. These advantages of DPC-NLCs proved the phospholipids complex played an essential role in NLCs formulation and showed the potential for intravenous administration of poorly soluble drugs.
- 11 January 2011
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 17 (4) , 443-456
A novel strategy for encapsulating poorly soluble drug into nanostructured lipid carriers for intravenous administration
The present study aimed to formulate dexamethasone (DXM), a poorly soluble drug, into nanostructured lipid carriers (NLCs) for intravenous administration by employing a phospholipids complex. Initially, dexamethasone-phospholipids complex (DPC) was synthesized and characterized. Subsequently, DPC was entrapped into NLCs and the process was optimized using spherical symmetric design-surface response methodology. Then, the characteristics, in vitro release behavior and physical stability of the optimized DPC loaded NLCs (DPC-NLCs) were investigated. Comparison between DPC-NLCs and free DXM loaded NLCs was also conducted in the aspects of particle size, entrapment efficiency (EE), drug loading efficiency (DL), initial release and zeta potential. The results showed the optimized DPC-NLCs were prepared with an average size of 189.33 ± 0.58 nm, EE of 89.82 ± 1.64%, DL of 2.13 ± 0.13% and good physical stability for 30 days. In vitro release profile exhibited an initial burst release followed by a prolonged release. Compared with free DXM loaded NLCs, the EE and DL of DPC-NLCs were higher while the initial release was lower. These advantages of DPC-NLCs proved the phospholipids complex played an essential role in NLCs formulation and showed the potential for intravenous administration of poorly soluble drugs.
- Open Access
- 1 July 2010
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 5, 487-497
In vivo biodistribution, anti-inflammatory, and hepatoprotective effects of liver targeting dexamethasone acetate loaded nanostructured lipid carrier system
We aimed to evaluate whether the enhancement of the liver accumulation and anti-inflammatory activity of dexamethasone acetate (DXMA) could be achieved by incorporating it into nanostructured lipid carrier (NLCs). DXMA-NLCs were prepared using a film dispersion-ultrasonication method and characterized in terms of particle size, PDI, zeta potential, differential scanning calorimetry, drug loading capacity, encapsulation efficiency, and in vitro release. The biodistribution and pharmacokinetics of DXMA-NLCs in mice were significantly different from those of the DXMA solution (DXMA-sol). The peak concentration of DXMA-NLCs was obtained half an hour after intravenous administration. More than 55.62% of the total administrated dose was present in the liver. An increase of 2.57 fold in the area under the curve was achieved when compared with that of DXMA-sol. DXMA-NLCs exhibited a significant anti-inflammatory and hepatoprotective effect on carrageenan-induced rats and carbon tetrachloride-induced mice compared with DXMA-sol. However, the effect was not in proportion to the dosage. The intermediate and low dosages presented better effects than DXMA-sol. All results indicate that NLCs, as a novel carrier for DXMA, has potential for the treatment of liver diseases, increasing the cure efficiency and decreasing the side effects on other tissues.
- 1 July 2010
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 5, 487-497
Open AccessIn vivo biodistribution, anti-inflammatory, and hepatoprotective effects of liver targeting dexamethasone acetate loaded nanostructured lipid carrier system
We aimed to evaluate whether the enhancement of the liver accumulation and anti-inflammatory activity of dexamethasone acetate (DXMA) could be achieved by incorporating it into nanostructured lipid carrier (NLCs). DXMA-NLCs were prepared using a film dispersion-ultrasonication method and characterized in terms of particle size, PDI, zeta potential, differential scanning calorimetry, drug loading capacity, encapsulation efficiency, and in vitro release. The biodistribution and pharmacokinetics of DXMA-NLCs in mice were significantly different from those of the DXMA solution (DXMA-sol). The peak concentration of DXMA-NLCs was obtained half an hour after intravenous administration. More than 55.62% of the total administrated dose was present in the liver. An increase of 2.57 fold in the area under the curve was achieved when compared with that of DXMA-sol. DXMA-NLCs exhibited a significant anti-inflammatory and hepatoprotective effect on carrageenan-induced rats and carbon tetrachloride-induced mice compared with DXMA-sol. However, the effect was not in proportion to the dosage. The intermediate and low dosages presented better effects than DXMA-sol. All results indicate that NLCs, as a novel carrier for DXMA, has potential for the treatment of liver diseases, increasing the cure efficiency and decreasing the side effects on other tissues.
- 1 April 2010
- Published by Georg Thieme Verlag KG in Arzneimittelforschung
- Vol. 60 (04) , 198-204
Oral characteristics of bergenin and the effect of absorption enhancers in situ, in vitro and in vivo
The purpose of this study was to explore the absorption characteristics of bergenin (CAS 477-90-7) and to improve its bioavailability by modulation of the gastrointestinal (GI) absorption using two enhancers (borneol and Poloxamer 188, resp. F68) based on in situ absorption model, in vitro Caco-2 monolayer and in vivo pharmacokinetics studies and comparing the results obtained. The effect of borneol and F68 on drug absorption was quantified at two concentration levels (1 or 4 mg/ml). The observations from in situ and in vitro model indicated that the oral absorption of bergenin is limited and passive diffusion could be the main manner. After oral administration alone (60 mg/kg), a biphasic characteristic was observed. AUC0→∞ was only 1.95 ± 0.29 μg × h/ml and Cmax was 0.44 ±0.11 μg/ml. From the results of in situ experiments, both of the enhancers were able to increase the absorption percentage of bergenin. Significantly increased (P < 0.05) apparent permeability was observed in Caco-2 cell monolayer. The oral bioavailability of bergenin in rats was improved in the presence of borneol or F68. AUC0→∞ increased significantly (P < 0.05) to 8.61 ± 3.74 and 3.41 ± 1.17 μg × h/ml, which were 4.42 and 1.75-fold higher with borneol and F68 than that of the control group, respectively. The enhanced bioavailability suggests that borneol and F68 could promote the absorption of bergenin in the GI tract.
- 1 April 2010
- Published by Georg Thieme Verlag KG in Arzneimittelforschung
- Vol. 60 (04) , 198-204
Oral characteristics of bergenin and the effect of absorption enhancers in situ, in vitro and in vivo
The purpose of this study was to explore the absorption characteristics of bergenin (CAS 477-90-7) and to improve its bioavailability by modulation of the gastrointestinal (GI) absorption using two enhancers (borneol and Poloxamer 188, resp. F68) based on in situ absorption model, in vitro Caco-2 monolayer and in vivo pharmacokinetics studies and comparing the results obtained. The effect of borneol and F68 on drug absorption was quantified at two concentration levels (1 or 4 mg/ml). The observations from in situ and in vitro model indicated that the oral absorption of bergenin is limited and passive diffusion could be the main manner. After oral administration alone (60 mg/kg), a biphasic characteristic was observed. AUC0→∞ was only 1.95 ± 0.29 μg × h/ml and Cmax was 0.44 ±0.11 μg/ml. From the results of in situ experiments, both of the enhancers were able to increase the absorption percentage of bergenin. Significantly increased (P < 0.05) apparent permeability was observed in Caco-2 cell monolayer. The oral bioavailability of bergenin in rats was improved in the presence of borneol or F68. AUC0→∞ increased significantly (P < 0.05) to 8.61 ± 3.74 and 3.41 ± 1.17 μg × h/ml, which were 4.42 and 1.75-fold higher with borneol and F68 than that of the control group, respectively. The enhanced bioavailability suggests that borneol and F68 could promote the absorption of bergenin in the GI tract.
- 7 December 2009
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 31 (1) , 127-136
Preparation, characterization and in vivo evaluation of bergenin-phospholipid complex
Aim: Methods: Results: Conclusion:
- 7 December 2009
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 31 (1) , 127-136
Preparation, characterization and in vivo evaluation of bergenin-phospholipid complex
Aim: Methods: Results: Conclusion: